Keros Therapeutics Newsroom

Cantor Fitzgerald Initiates Keros Therapeutics(KROS.US) With Buy Rating

Futu NewsOct 24 18:31 · Ratings

Scotiabank Initiates Coverage On Keros Therapeutics With Sector Outperform Rating, Announces Price Target of $77

Analyst UpgradesOct 16 22:36

Express News | Keros Therapeutics Appoints Yung H. Chyung, M.d., as Chief Medical Officer

BreakingsOct 16 20:00

"Weight-loss miracle drug" causing muscle loss, biotechnology companies like Regeneron Pharmaceuticals (REGN.US) are developing new treatments.

Wegovy and Zepbound, along with other GLP-1 class drugs, have significant effects on weight loss, but this weight loss largely reduces muscle mass.

Zhitong FinanceOct 14 14:42

Weight Loss Drugs Have One Big Issue; These Companies Want to Fix It

Seeking AlphaOct 13 01:58

Analysts Have Conflicting Sentiments on These Healthcare Companies: Ironwood Pharma (IRWD), Travere Therapeutics (TVTX) and Keros Therapeutics (KROS)

TipRanksOct 4 14:41 · Ratings

Truist Financial Maintains Keros Therapeutics(KROS.US) With Buy Rating

Futu NewsOct 2 19:31 · Ratings

Truist Financial Reaffirms Their Buy Rating on Keros Therapeutics (KROS)

TipRanksOct 2 19:07 · Ratings

Express News | Keros Therapeutics: To Present Topline Data in Q2 2025

BreakingsSep 30 20:09

Express News | Keros Therapeutics : Completes Enrollment of Tropos Phase 2 Trial

BreakingsSep 30 20:09

Kronos Bio To Present Data At ACR Convergence 2024 To Support P300 KAT Inhibition As An Approach To Anti-Inflammatory Therapy

BenzingaSep 25 21:08

Guggenheim Initiates Keros Therapeutics at Buy With $96 Price Target

MT NewswiresSep 23 17:37 · Ratings

Guggenheim Initiates Keros Therapeutics(KROS.US) With Buy Rating, Announces Target Price $96

Guggenheim analyst Vamil Divan initiates coverage on $Keros Therapeutics(KROS.US)$ with a buy rating, and sets the target price at $96.According to TipRanks data, the analyst has a success rate of 53.

Futu NewsSep 23 17:33 · Ratings

B of A Securities Maintains Buy on Keros Therapeutics, Lowers Price Target to $76

BenzingaSep 13 01:47 · Ratings

Keros Therapeutics Analyst Ratings

BenzingaSep 13 01:46 · Ratings

BofA Securities Maintains Keros Therapeutics(KROS.US) With Buy Rating, Cuts Target Price to $76

BofA Securities analyst Jason Zemansky maintains $Keros Therapeutics(KROS.US)$ with a buy rating, and adjusts the target price from $81 to $76.According to TipRanks data, the analyst has a success

Futu NewsSep 12 19:31 · Ratings

Analysts Have Conflicting Sentiments on These Healthcare Companies: Medtronic (MDT), Harmony Biosciences Holdings (HRMY) and Keros Therapeutics (KROS)

TipRanksSep 12 18:40 · Ratings

Keros Therapeutics Up Over 12%, on Pace for Largest Percent Increase Since January -- Data Talk

Dow JonesSep 5 02:46

Keros Therapeutics Shares Are Trading Higher After the Company Announced It Closed Screening for Its Phase 2 Clinical TROPOS Trial.

BenzingaSep 3 22:33

Express News | Keros Therapeutics Inc - to Present Topline Data in Q2 2025

BreakingsSep 3 20:02